Work

Therapeutics for Rheumatoid Arthritis: A Phase 4 Clinical Trial Analysis With a Focus on Disability Outcomes

Year: 2026

Type: article

Abstract: Background Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by persistent synovitis, cartilage damage, progressive disability, and a significant decline in quality of life. The advent of biologics and small molecule inhibitors has substantially improved disease management and reduced disability. However, the long‐term impact of these therapies on disease progression and functional outcomes remains a critical area of ongoing research. Objective This analysis aims to evaluate the efficacy, safety, and disability outcomes of various therapeutics for RA by analyzing completed Phase 4 interventional clinical trials registered on ClinicalTrials.gov . Methods A systematic analysis of ClinicalTrials.gov was conducted on October 28, 2024, focusing on completed Phase 4 interventional studies with results, targeting RA treatments. Inclusion criteria covered studies involving biologics, small molecule inhibitors, and combination therapies aimed at managing RA. Key outcome measures such as Disease Activity Score 28 (DAS28), The American College of Rheumatology response criteria, patient‐reported outcomes, and disability‐related measures were extracted and analyzed. Results The analysis found that therapeutic advances, including TNF inhibitors, IL‐6R inhibitors, and JAK inhibitors, demonstrated significant efficacy in reducing disease activity and improving functional outcomes. Long‐term data revealed that these treatments delay or reduce disability progression, although differences in safety profiles were noted, particularly with JAK inhibitors showing an increased risk of thromboembolic events. Conclusion Phase 4 clinical trials provide real‐world evidence of the effectiveness and safety of RA therapeutics, with a positive impact on disability management. Ongoing research and postmarketing surveillance are essential to optimizing treatment strategies and addressing residual disability in RA patients.

Source: Journal of Clinical Pharmacy and Therapeutics

DOI: 10.1155/jcpt/8453371